Prof Marie Pierre Bonnet = @MariePierreBon2 (yay! for #SoMe) and she presents on anemia in #ObAnes at #OAA3dc2022 (photo better than podium ones). Definition of anemia in pregnancy: 110 or greater (11.0g/dL). Worldwide disparities.
Iron deficiency dominates anemia in pregnancy. Iron deficiency is innocuous, right? Perhaps not in pregnancy. Maternal iron deficiency affects more than just Hb. It is associated with adverse outcomes. #OAA3dc2022
@MariePierreBon2 highlights anemia’s impact on maternal mortality (@BJOGTweets@mbrrace): aOR 3.6! Not just mortality, but morbidity burden as well (@Anaes_Journal). The psychological impact of maternal anemia is acknowledged - postpartum depression & cognition #OAA3dc2022
Systematic prevention of anemia in pregnancy is difficult - poor consensus, wide variation. @NICEComms dropped iron supplementation in 2021 update. No consensus from USA: @CDCgov recommends in 1998, lost in 2015, back in @acog recommendations 2021 - low dose iron #OAA3dc2022
@cochranecollab 2015 found poor evidence for iron supplementation routinely. @NATAforum recommendations 2019 focused on population factors: supplement routinely if high risk, test ferretin if not. @cochranecollab found intermittent iron supplementation viable #OAA3dc2022
Curative treatment - is it possible? Oral or IV? Both have pro’s and con’s. IV iron may be superior, but does it impact on clinical outcomes? #OAA3dc2022
IV iron definitely impacts anemia at delivery more than oral iron, but no difference in birth weight, gestational age or umbilical Hb (@BMJ_Open). IV did improve quality of life at 4 weeks after starting treatment. #OAA3dc2022
As Peri-delivery physicians who may encounter #OBAnes patients during their pregnancy, we should possibly ensure treatment of anemia? @MariePierreBon2 recommends an algorithmic approach. #OAA3dc2022
Next up at #CASAM2023 - fittingly keeping the most important academic session to last: #OBAnes @ValZaph moderating the Maternal Experience and Outcomes: Improving the care we provide. @DrWesleyEdwards
Dr Christina Lamontagne kicks off the session with: Use of Dexmedetomidine in improving maternal experience and outcomes. Nothing to disclose. Then an important disclosure: All indications discussed are OFF LABEL in Canada. Objectives. #OBAnes#CASAM2023
Why does Dr Lamontagne use a lot of dexmedetomidine (not only in #OBAnes mind)? Clinical pharmacology of dexmedetomidine (1): highly selective alpha-2 agonist; sedation WITHOUT amnesia at locus coeruleus. #CASAM2023
Dr Ning Nan Wang introduces @harshamd5 to open the chronic pain session: Perioperative use of opioid in the context of Opioid Epidemic. #CASAM2023
The opioid crisis isn’t new - China probably remembers the Opium wars that helped establish a British foothold on the continent. Opioids and OUR crisis. Is what we fear the real crisis? Are opioid-related deaths due to surgical prescriptions? No, mostly due to street fentanyl.… twitter.com/i/web/status/1…
Opioid use around the time of surgery. Understanding nociception vs pain. Does eliminating opioids during surgery make a difference - no definitive conclusions. #CASAM2023
PPH: a focus on coagulation is kicked off by Dr Karine Doyon (a hematologist). Objectives. Canada ranked 39th in world in maternal mortality - not sure if that’s good. We’re doing better than USA. #OBAnes#CASAM2023
Causes of coagulopathy in pregnancy - Dr Doyon won’t be discussing inherited disorders. The focus will be on the acquired hemorrhagic disorders. #OBAnes#CASAM2023
Pregnancy-associated mortality ≈ maternal mortality. #OBAnes 0.2% - doing well (wonder what the denominator is?), so Elmo could ask why are we worried? #SOAPAM2023